FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895870246> ?p ?o ?g. }

• W2895870246 abstract "Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.Patients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.Arm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached. Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months.The addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.Clinicaltrials.gov identifier: NCT01472081 . Registered 16 November 2011." @default.
• W2895870246 created "2018-10-26" @default.
• W2895870246 creator A5001783218 @default.
• W2895870246 creator A5007052233 @default.
• W2895870246 creator A5008288310 @default.
• W2895870246 creator A5016385021 @default.
• W2895870246 creator A5025529463 @default.
• W2895870246 creator A5032422193 @default.
• W2895870246 creator A5037195922 @default.
• W2895870246 creator A5054206895 @default.
• W2895870246 creator A5060348071 @default.
• W2895870246 creator A5068644454 @default.
• W2895870246 creator A5080500055 @default.
• W2895870246 creator A5085328645 @default.
• W2895870246 creator A5087150696 @default.
• W2895870246 creator A5088232810 @default.
• W2895870246 creator A5089516753 @default.
• W2895870246 creator A5091859782 @default.
• W2895870246 date "2018-10-22" @default.
• W2895870246 modified "2023-10-12" @default.
• W2895870246 title "Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study" @default.
• W2895870246 cites W1536286673 @default.
• W2895870246 cites W1564728191 @default.
• W2895870246 cites W1987446429 @default.
• W2895870246 cites W2047871200 @default.
• W2895870246 cites W2099088585 @default.
• W2895870246 cites W2103689170 @default.
• W2895870246 cites W2113073012 @default.
• W2895870246 cites W2116949558 @default.
• W2895870246 cites W2125112000 @default.
• W2895870246 cites W2128758225 @default.
• W2895870246 cites W2148706732 @default.
• W2895870246 cites W2156408558 @default.
• W2895870246 cites W2157262448 @default.
• W2895870246 cites W2162424705 @default.
• W2895870246 cites W2222086386 @default.
• W2895870246 cites W2231431230 @default.
• W2895870246 cites W2309303154 @default.
• W2895870246 cites W2316731546 @default.
• W2895870246 cites W2327663787 @default.
• W2895870246 cites W2371138393 @default.
• W2895870246 cites W2394893668 @default.
• W2895870246 cites W2415950182 @default.
• W2895870246 cites W2512493222 @default.
• W2895870246 cites W2558408743 @default.
• W2895870246 cites W2561100838 @default.
• W2895870246 cites W2572174216 @default.
• W2895870246 cites W2590029130 @default.
• W2895870246 cites W2724506765 @default.
• W2895870246 cites W2748036232 @default.
• W2895870246 cites W2764197427 @default.
• W2895870246 cites W2779503684 @default.
• W2895870246 cites W2783234388 @default.
• W2895870246 cites W2785838318 @default.
• W2895870246 cites W2790175716 @default.
• W2895870246 cites W2791442381 @default.
• W2895870246 cites W2792699081 @default.
• W2895870246 cites W2792937256 @default.
• W2895870246 cites W2801270371 @default.
• W2895870246 cites W2810134512 @default.
• W2895870246 cites W2891290712 @default.
• W2895870246 cites W2891366395 @default.
• W2895870246 cites W3001232216 @default.
• W2895870246 cites W4233481919 @default.
• W2895870246 doi "https://doi.org/10.1186/s40425-018-0420-0" @default.
• W2895870246 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6416882" @default.
• W2895870246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30871617" @default.
• W2895870246 hasPublicationYear "2018" @default.
• W2895870246 type Work @default.
• W2895870246 sameAs 2895870246 @default.
• W2895870246 citedByCount "141" @default.
• W2895870246 countsByYear W28958702462019 @default.
• W2895870246 countsByYear W28958702462020 @default.
• W2895870246 countsByYear W28958702462021 @default.
• W2895870246 countsByYear W28958702462022 @default.
• W2895870246 countsByYear W28958702462023 @default.
• W2895870246 crossrefType "journal-article" @default.
• W2895870246 hasAuthorship W2895870246A5001783218 @default.
• W2895870246 hasAuthorship W2895870246A5007052233 @default.
• W2895870246 hasAuthorship W2895870246A5008288310 @default.
• W2895870246 hasAuthorship W2895870246A5016385021 @default.
• W2895870246 hasAuthorship W2895870246A5025529463 @default.
• W2895870246 hasAuthorship W2895870246A5032422193 @default.
• W2895870246 hasAuthorship W2895870246A5037195922 @default.
• W2895870246 hasAuthorship W2895870246A5054206895 @default.
• W2895870246 hasAuthorship W2895870246A5060348071 @default.
• W2895870246 hasAuthorship W2895870246A5068644454 @default.
• W2895870246 hasAuthorship W2895870246A5080500055 @default.
• W2895870246 hasAuthorship W2895870246A5085328645 @default.
• W2895870246 hasAuthorship W2895870246A5087150696 @default.
• W2895870246 hasAuthorship W2895870246A5088232810 @default.
• W2895870246 hasAuthorship W2895870246A5089516753 @default.
• W2895870246 hasAuthorship W2895870246A5091859782 @default.
• W2895870246 hasBestOaLocation W28958702461 @default.
• W2895870246 hasConcept C121608353 @default.
• W2895870246 hasConcept C126322002 @default.
• W2895870246 hasConcept C126894567 @default.
• W2895870246 hasConcept C143998085 @default.
• W2895870246 hasConcept C197934379 @default.
• W2895870246 hasConcept C203092338 @default.

• next